Senior Vice President for Corporate Development, Biogen
Richard Brudnick is Senior Vice President for Corporate Development at Biogen. Upon the spinoff of Biogen’s hemophilia and blood disorders business into Bioverativ, he will be Executive Vice President of Business Development & Alliance Management of the newly formed, independent and publicly traded company. During his years with Biogen, Richard was responsible for business development transactions which have resulted in several of Biogen’s marketed and late stage products, including TECFIDERA, ZINBRYTA, ELOCTATE, ALPROLIX, BENEPALI, FLIXABI, SPINRAZA and raxatrigine as well as its joint venture with Samsung to develop and commercialize biosimilar products including BENEPALI and FLIXABI.
Before joining Biogen, Richard was CEO of a regional pharmaceutical distribution business which he sold to a strategic buyer, co-founded two companies, and was a strategy consultant at Bain & Company. He earned his undergraduate and graduate degrees at MIT. Richard enjoys boating, scuba diving, blues music, and spending time with his wife and three sons. He also enjoys history and reading the biographies of people who lived through and shaped the events which help define our times.